Clayton B Hess1, Dominique L Rash1, Megan E Daly1, D Gregory Farwell2, John Bishop3, Andrew T Vaughan1, Machelle D Wilson4, Allen M Chen1. 1. Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento. 2. Department of Otolaryngology-Head and Neck Surgery, University of California Davis Comprehensive Cancer Center, Sacramento. 3. Department of Pathology, University of California Davis Comprehensive Cancer Center, Sacramento. 4. Division of Biostatistics, Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento.
Abstract
IMPORTANCE: Survival of patients with head and neck cancer can be affected by competing causes of mortality, as well as comorbidities that result in radiation treatment interruptions. OBJECTIVE: To discern how differences in preexisting medical and psychosocial comorbidities potentially influence adherence to radiation therapy according to human papillomavirus (HPV) status. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis at a comprehensive cancer center of 162 consecutive patients with locally advanced squamous cell carcinoma of the oropharynx treated with primary chemoradiation (n = 95) or primary surgery followed by adjuvant radiation (n = 67). Immunostaining for p16 was used to determine HPV status. MAIN OUTCOMES AND MEASURES: Difference in alcohol, tobacco, and marijuana use was compared between patients with HPV-positive and HPV-negative tumors, as well as the prevalence of the following comorbidities: diabetes mellitus, chronic obstructive pulmonary disease (COPD), anxiety disorder, and major depression. The number of total missed treatment days was analyzed as both a continuous and categorical variable. RESULTS: Rates of self-reported heavy alcohol use (47% vs 16%; P = .02) and any marijuana use (47% vs 23%; P = .003) were significantly higher among HPV-negative patients. Fifty-four percent of HPV-positive patients self-identified as never smokers, compared with only 12% of HPV-negative patients (P < .001). HPV-negative patients had more missed treatment days (mean, 2.8 vs 1.7 days; P = .02), as well as an increased rate of at least 5 missed days (24% vs 10%; P = .04), and higher prevalences of COPD (12% vs 7%; P = .37) and anxiety disorder (12% vs 6%; P = .35). CONCLUSIONS AND RELEVANCE: Pronounced differences exist in lifestyle habits between patients with HPV-negative and HPV-positive oropharyngeal cancer at diagnosis. These differences, as well as those of medical and psychosocial burden, may contribute to observed discrepancies in treatment adherence and need to be considered in outcomes reporting and clinical trial design.
IMPORTANCE: Survival of patients with head and neck cancer can be affected by competing causes of mortality, as well as comorbidities that result in radiation treatment interruptions. OBJECTIVE: To discern how differences in preexisting medical and psychosocial comorbidities potentially influence adherence to radiation therapy according to human papillomavirus (HPV) status. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis at a comprehensive cancer center of 162 consecutive patients with locally advanced squamous cell carcinoma of the oropharynx treated with primary chemoradiation (n = 95) or primary surgery followed by adjuvant radiation (n = 67). Immunostaining for p16 was used to determine HPV status. MAIN OUTCOMES AND MEASURES: Difference in alcohol, tobacco, and marijuana use was compared between patients with HPV-positive and HPV-negative tumors, as well as the prevalence of the following comorbidities: diabetes mellitus, chronic obstructive pulmonary disease (COPD), anxiety disorder, and major depression. The number of total missed treatment days was analyzed as both a continuous and categorical variable. RESULTS: Rates of self-reported heavy alcohol use (47% vs 16%; P = .02) and any marijuana use (47% vs 23%; P = .003) were significantly higher among HPV-negative patients. Fifty-four percent of HPV-positive patients self-identified as never smokers, compared with only 12% of HPV-negative patients (P < .001). HPV-negative patients had more missed treatment days (mean, 2.8 vs 1.7 days; P = .02), as well as an increased rate of at least 5 missed days (24% vs 10%; P = .04), and higher prevalences of COPD (12% vs 7%; P = .37) and anxiety disorder (12% vs 6%; P = .35). CONCLUSIONS AND RELEVANCE: Pronounced differences exist in lifestyle habits between patients with HPV-negative and HPV-positive oropharyngeal cancer at diagnosis. These differences, as well as those of medical and psychosocial burden, may contribute to observed discrepancies in treatment adherence and need to be considered in outcomes reporting and clinical trial design.
Authors: Drew C Brotherston; Ian Poon; Tuyen Le; Martin Leung; Alex Kiss; Jolie Ringash; Judith Balogh; Justin Lee; James R Wright Journal: Head Neck Date: 2012-03-20 Impact factor: 3.147
Authors: Megan Dann Fesinmeyer; Vivek Mehta; David Blough; Lauri Tock; Scott D Ramsey Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-03 Impact factor: 7.038
Authors: Jens P Klussmann; Soenke J Weissenborn; Ulrike Wieland; Volker Dries; Hans E Eckel; Herbert J Pfister; Pawel G Fuchs Journal: Med Microbiol Immunol Date: 2002-09-14 Impact factor: 3.402
Authors: Bertrand Baujat; Jean Bourhis; Pierre Blanchard; Jens Overgaard; Kian K Ang; Michelle Saunders; Aurélie Le Maître; Jacques Bernier; Jean Claude Horiot; Emilie Maillard; Thomas F Pajak; Michael G Poulsen; Abderrahmane Bourredjem; Brian O'Sullivan; Werner Dobrowsky; Hliniak Andrzej; Krzystof Skladowski; John H Hay; Luiz Hj Pinto; Karen K Fu; Carlo Fallai; Richard Sylvester; Jean Pierre Pignon Journal: Cochrane Database Syst Rev Date: 2010-12-08
Authors: S Andrew Skillington; Dorina Kallogjeri; James S Lewis; Jay F Piccirillo Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-03-01 Impact factor: 6.223
Authors: Matthew J Nyflot; Tim J Kruser; Anne M Traynor; Deepak Khuntia; David T Yang; Gregory K Hartig; Timothy M McCulloch; Peggy A Wiederholt; Lindell R Gentry; Tien Hoang; Robert Jeraj; Paul M Harari Journal: Int J Radiat Oncol Biol Phys Date: 2015-02-03 Impact factor: 7.038
Authors: Daniel R Dickstein; Marc A Egerman; Anthony H Bui; John T Doucette; Sonam Sharma; Jerry Liu; Vishal Gupta; Brett A Miles; Eric Genden; William H Westra; Krzysztof Misiukiewicz; Marshall R Posner; Richard L Bakst Journal: Oral Oncol Date: 2020-08-31 Impact factor: 5.972
Authors: Aaron D Falchook; Rebecca Green; Mary E Knowles; Robert J Amdur; William Mendenhall; David N Hayes; Juneko E Grilley-Olson; Jared Weiss; Bryce B Reeve; Sandra A Mitchell; Ethan M Basch; Bhishamjit S Chera Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: S Andrew Skillington; Dorina Kallogjeri; James S Lewis; Jay F Piccirillo Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: Sarah Schimansky; Samantha Lang; Rhona Beynon; Christopher Penfold; Amy Davies; Andrea Waylen; Steve Thomas; Miranda Pring; Michael Pawlita; Tim Waterboer; Andy Ness Journal: Head Neck Date: 2018-12-14 Impact factor: 3.147
Authors: Lan He; Priscilla T Y Law; Siaw Shi Boon; Chuqing Zhang; Wendy C S Ho; Lawrence Banks; C K Wong; Juliana C N Chan; Paul K S Chan Journal: PLoS One Date: 2016-10-17 Impact factor: 3.240